SlideShare une entreprise Scribd logo
1  sur  20
AMSTERDAM  4  Septembre 2010
Goedendag, Hello, Bonjour,
De vereniging is opgericht in  juni 2006. The association was founded in June 2006. L'association a été créée en Juin 2006.
Zij ondersteunt patiënten met „ caps“ cryopyrine associated périodic syndroom. It provides assistance to patients « caps » cryopyrine associated periodic syndrome. Elle apporte son aide aux malades « caps » Syndrome périodique associé à la cryopyrine
Drie ziektebeelden : Three conditions : Trois pathologies :
Koude Netelroos    of  FCAS  familie cold zelf-inflammatory syndroom,   Cold urticaria  or FCAS family cold  auto-inflammatory syndrome, Urticaire au froid  ou  FCAS  familial cold auto-inflammatory syndrome,
MWS  Muckle en Wells syndroom, MWS Muckle and Wells syndrome, MWS Muckle et Wells Syndrome,
CINCA  Chronisch, kinderen, neurologisch, huid, gewrichten. CINCA Chronic infantile neurological cutaneous articular. CINCA Chronique, Infantile, Neurologique,Cutané, Articulaire.
De symptomen : Symptoms : Les symptômes :
het meest zichtbaar: Conjunctivitis en netelroos, most visible :  conjunctivitis and urticaria, les plus visibles :  Conjonctivite et urticaire
netelroos ,  urticaria , urticaire
Pijnlijk maar niet- zichtbaar :  Gewrichtsaandoeningen, Painful but not visible : Articular, Douloureux mais non visibles : les atteintes articulaires
Het meest hinderlijk:  waarnemingsdoofheid, kan met hoortoestellen verbeteren The most troublesome: sensorineural hearing loss, can still be paired,   La plus gênante : la surdité de perception, peut être néanmoins appareillée
Het ernstigst: amylose, uvéite, hersenvliesontsteking. The most serious: amyloidosis, uveitis, meningitis. Les plus graves : amylose, uvéite, méningite.
De 3 gevallen zijn ongeneeslijk maar behandelbaar, dank zij anakinra, rinolacept en canakinumab. The 3 cases can be treated but not cured, with anakinra,  rinolacept, and canakinumab. Les 3 cas peuvent être soignés mais non guéris, grâce à l’anakinra, le rinolacept et le canakinumab.
Het hoofdkantoor van AMWS is gevestigd in Carquefou, stad die met EERSEL, in Noord Brabant, dichtbij Eindhoven (Nederland) vriendschapsbanden heeft. The headquarters is AMWS Carquefou, Eersel sister city in North Brabant, near Eindhoven (Netherlands) Le siège social de l’AMWS est à Carquefou, ville jumelée avec EERSEL, dans le Nord Brabant, près de Eindhoven (Pays-Bas)
 
 
Bedankt voor Uw aandacht.   Thank you for your attention.   Merci de votre attention. Met dank aan de vertalers,   thank you with the translators  merci aux traducteurs  Maarten Dierks  Voorzitter  Jumelagecomité Eersel-Carquefou,  Gildas Pépion  Docteur en pharmacie  Carquefou  et .... Denis Costello ...en direct .
14, rue Panneton  44470 Carquefou  France  02 40 50 85 30  courriel  [email_address] .fr   site www.amws-cinca.eu

Contenu connexe

Similaire à AMWS CINCA

Dossier acouphènes - sante corps esprit
Dossier acouphènes - sante corps espritDossier acouphènes - sante corps esprit
Dossier acouphènes - sante corps espritdavid bonnin
 
Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.
Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.
Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.Khadija Moussayer
 
Ière Journée des angioedemes au Maroc
Ière Journée des angioedemes au MarocIère Journée des angioedemes au Maroc
Ière Journée des angioedemes au MarocKhadija Moussayer
 
Alzheimr: comment vous aider à faire face
Alzheimr: comment vous aider à faire faceAlzheimr: comment vous aider à faire face
Alzheimr: comment vous aider à faire facealzheimer.tunisie
 
Congrès international sur le syndrome des bébés secoués.
Congrès international sur le syndrome des bébés secoués.Congrès international sur le syndrome des bébés secoués.
Congrès international sur le syndrome des bébés secoués.Réseau Pro Santé
 
Epidemia
EpidemiaEpidemia
EpidemiaMaff_88
 

Similaire à AMWS CINCA (7)

Dossier acouphènes - sante corps esprit
Dossier acouphènes - sante corps espritDossier acouphènes - sante corps esprit
Dossier acouphènes - sante corps esprit
 
Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.
Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.
Maladie de Raynaud : 3 à 5 % de la population mondiale en est touchée.
 
Ière Journée des angioedemes au Maroc
Ière Journée des angioedemes au MarocIère Journée des angioedemes au Maroc
Ière Journée des angioedemes au Maroc
 
R et p décembre 2017
R et p décembre 2017R et p décembre 2017
R et p décembre 2017
 
Alzheimr: comment vous aider à faire face
Alzheimr: comment vous aider à faire faceAlzheimr: comment vous aider à faire face
Alzheimr: comment vous aider à faire face
 
Congrès international sur le syndrome des bébés secoués.
Congrès international sur le syndrome des bébés secoués.Congrès international sur le syndrome des bébés secoués.
Congrès international sur le syndrome des bébés secoués.
 
Epidemia
EpidemiaEpidemia
Epidemia
 

Plus de EURORDIS - Rare Diseases Europe

RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...EURORDIS - Rare Diseases Europe
 
RareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare diseaseRareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare diseaseEURORDIS - Rare Diseases Europe
 
RareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients GloballyRareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients GloballyEURORDIS - Rare Diseases Europe
 
Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...EURORDIS - Rare Diseases Europe
 
Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...EURORDIS - Rare Diseases Europe
 
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...EURORDIS - Rare Diseases Europe
 
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe" Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe" EURORDIS - Rare Diseases Europe
 
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"EURORDIS - Rare Diseases Europe
 
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"EURORDIS - Rare Diseases Europe
 
Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...EURORDIS - Rare Diseases Europe
 
Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"EURORDIS - Rare Diseases Europe
 
Workshop 4 - "Feedback from the 15 National Conferences on Research policy"
Workshop 4 - "Feedback from the 15 National Conferences on Research policy"Workshop 4 - "Feedback from the 15 National Conferences on Research policy"
Workshop 4 - "Feedback from the 15 National Conferences on Research policy"EURORDIS - Rare Diseases Europe
 
Conference 4 - The patient experience in the development and implementation ...
Conference 4 - The patient experience  in the development and implementation ...Conference 4 - The patient experience  in the development and implementation ...
Conference 4 - The patient experience in the development and implementation ...EURORDIS - Rare Diseases Europe
 

Plus de EURORDIS - Rare Diseases Europe (20)

RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...RareConnect.org webinar How to use Twitter to build your online rare disease ...
RareConnect.org webinar How to use Twitter to build your online rare disease ...
 
RareConnect.org Update 2016
RareConnect.org Update 2016RareConnect.org Update 2016
RareConnect.org Update 2016
 
RareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare diseaseRareConnect.org webinar: How to start an awareness day for your rare disease
RareConnect.org webinar: How to start an awareness day for your rare disease
 
Living with TRAPS poll results
Living with TRAPS poll resultsLiving with TRAPS poll results
Living with TRAPS poll results
 
Pitt Hopkins syndrome community on RareConnect.org
Pitt Hopkins syndrome community on RareConnect.orgPitt Hopkins syndrome community on RareConnect.org
Pitt Hopkins syndrome community on RareConnect.org
 
The Value of Online Communities
The Value of Online CommunitiesThe Value of Online Communities
The Value of Online Communities
 
Updates to RareConnect.org in 2014
Updates to RareConnect.org in 2014Updates to RareConnect.org in 2014
Updates to RareConnect.org in 2014
 
RareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients GloballyRareConnect.org - Connecting Rare Disease Patients Globally
RareConnect.org - Connecting Rare Disease Patients Globally
 
Rare disease day 2011 highlights
Rare disease day 2011 highlightsRare disease day 2011 highlights
Rare disease day 2011 highlights
 
Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...Results of Survey on the role of Patient Groups in Research and their priorit...
Results of Survey on the role of Patient Groups in Research and their priorit...
 
Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...Results of a survey on the role of Patient Groups in Research and their prio...
Results of a survey on the role of Patient Groups in Research and their prio...
 
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
Conference 1 - EURORDIS’ recommendations for National Plans, Yann le Cam, EUR...
 
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe" Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
Workshop 1 - "The EU tender on Newborn Screening for rare disordersin Europe"
 
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
Workshop 7 - "EUROCAT Study on Prevention of Congenital Anomalies"
 
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
Workshop 3 - "Outcome of the RD Task Force and EPPOSI Workshop"
 
Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...Conference 5 - “Patient’s Experience in the Development and Implementation of...
Conference 5 - “Patient’s Experience in the Development and Implementation of...
 
Workshop 3 - "Presentation of the Epi-Rare project"
Workshop 3 - "Presentation of the Epi-Rare project"Workshop 3 - "Presentation of the Epi-Rare project"
Workshop 3 - "Presentation of the Epi-Rare project"
 
Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"Workshop 3 - "Presentation of the concept, definitions and terminology"
Workshop 3 - "Presentation of the concept, definitions and terminology"
 
Workshop 4 - "Feedback from the 15 National Conferences on Research policy"
Workshop 4 - "Feedback from the 15 National Conferences on Research policy"Workshop 4 - "Feedback from the 15 National Conferences on Research policy"
Workshop 4 - "Feedback from the 15 National Conferences on Research policy"
 
Conference 4 - The patient experience in the development and implementation ...
Conference 4 - The patient experience  in the development and implementation ...Conference 4 - The patient experience  in the development and implementation ...
Conference 4 - The patient experience in the development and implementation ...
 

AMWS CINCA

  • 1. AMSTERDAM 4 Septembre 2010
  • 3. De vereniging is opgericht in juni 2006. The association was founded in June 2006. L'association a été créée en Juin 2006.
  • 4. Zij ondersteunt patiënten met „ caps“ cryopyrine associated périodic syndroom. It provides assistance to patients « caps » cryopyrine associated periodic syndrome. Elle apporte son aide aux malades « caps » Syndrome périodique associé à la cryopyrine
  • 5. Drie ziektebeelden : Three conditions : Trois pathologies :
  • 6. Koude Netelroos   of  FCAS  familie cold zelf-inflammatory syndroom, Cold urticaria or FCAS family cold auto-inflammatory syndrome, Urticaire au froid ou FCAS familial cold auto-inflammatory syndrome,
  • 7. MWS  Muckle en Wells syndroom, MWS Muckle and Wells syndrome, MWS Muckle et Wells Syndrome,
  • 8. CINCA Chronisch, kinderen, neurologisch, huid, gewrichten. CINCA Chronic infantile neurological cutaneous articular. CINCA Chronique, Infantile, Neurologique,Cutané, Articulaire.
  • 9. De symptomen : Symptoms : Les symptômes :
  • 10. het meest zichtbaar: Conjunctivitis en netelroos, most visible : conjunctivitis and urticaria, les plus visibles : Conjonctivite et urticaire
  • 11. netelroos , urticaria , urticaire
  • 12. Pijnlijk maar niet- zichtbaar : Gewrichtsaandoeningen, Painful but not visible : Articular, Douloureux mais non visibles : les atteintes articulaires
  • 13. Het meest hinderlijk: waarnemingsdoofheid, kan met hoortoestellen verbeteren The most troublesome: sensorineural hearing loss, can still be paired, La plus gênante : la surdité de perception, peut être néanmoins appareillée
  • 14. Het ernstigst: amylose, uvéite, hersenvliesontsteking. The most serious: amyloidosis, uveitis, meningitis. Les plus graves : amylose, uvéite, méningite.
  • 15. De 3 gevallen zijn ongeneeslijk maar behandelbaar, dank zij anakinra, rinolacept en canakinumab. The 3 cases can be treated but not cured, with anakinra, rinolacept, and canakinumab. Les 3 cas peuvent être soignés mais non guéris, grâce à l’anakinra, le rinolacept et le canakinumab.
  • 16. Het hoofdkantoor van AMWS is gevestigd in Carquefou, stad die met EERSEL, in Noord Brabant, dichtbij Eindhoven (Nederland) vriendschapsbanden heeft. The headquarters is AMWS Carquefou, Eersel sister city in North Brabant, near Eindhoven (Netherlands) Le siège social de l’AMWS est à Carquefou, ville jumelée avec EERSEL, dans le Nord Brabant, près de Eindhoven (Pays-Bas)
  • 17.  
  • 18.  
  • 19. Bedankt voor Uw aandacht. Thank you for your attention. Merci de votre attention. Met dank aan de vertalers, thank you with the translators merci aux traducteurs Maarten Dierks Voorzitter Jumelagecomité Eersel-Carquefou, Gildas Pépion Docteur en pharmacie Carquefou et .... Denis Costello ...en direct .
  • 20. 14, rue Panneton 44470 Carquefou France 02 40 50 85 30 courriel [email_address] .fr site www.amws-cinca.eu